Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease

Daiki Katagishi; Daisuke Yasuda; Kyoko Takahashi; Shigeo Nakamura; Tadahiko Mashino; Tomoyuki Ohe

doi:10.1016/j.bmcl.2022.129121

Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease

Bioorg Med Chem Lett. 2023 Jan 15:80:129121. doi: 10.1016/j.bmcl.2022.129121. Epub 2022 Dec 29.

Authors

Daiki Katagishi¹, Daisuke Yasuda¹, Kyoko Takahashi², Shigeo Nakamura², Tadahiko Mashino¹, Tomoyuki Ohe³

Affiliations

¹ Department of Pharmaceutical Sciences, Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo, Japan.
² Department of Chemistry, Nippon Medical School, 1-7-1 Kyonan-cho, Musashino-shi, Tokyo, Japan.
³ Department of Pharmaceutical Sciences, Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo, Japan. Electronic address: ohe-tm@pha.keio.ac.jp.

Abstract

COVID-19 is an ongoing worldwide pandemic. Even today, there is a need for the development of effective therapeutic agents. SARS-CoV-2 is known as the causative virus of COVID-19, and its main protease is one of the enzymes essential for its growth and is considered a drug discovery target. In this study, we evaluated the inhibitory activities of a variety of fullerene derivatives, including newly synthesized derivatives, against the main protease of SARS-CoV-2. As a result, the malonic acid-type fullerene derivatives showed the strongest inhibitory activity.

Keywords: COVID-19; Fullerene; Main protease; SARS-CoV-2.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antiviral Agents / pharmacology
COVID-19*
Coronavirus 3C Proteases
Fullerenes* / pharmacology
Humans
Molecular Docking Simulation
Protease Inhibitors / pharmacology
SARS-CoV-2

Substances

3C-like proteinase, SARS-CoV-2
Fullerenes
Protease Inhibitors
Antiviral Agents
Coronavirus 3C Proteases